Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$44.43 USD
+1.06 (2.44%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $44.45 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Setting Expectations For PATHFNDR-2; A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine Comes Up Aces Again; Price Target Up to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CRNX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tens Across the Board for Paltusotine in PATHFNDR-1; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Enthusiasm For Paltusotine is Clear With Readout on Deck; Adjusting PT to $33 With Setback for CHI Program; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from our Conversation with Crinetics Pharmaceuticals and ENDO 2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Previewing PATHFNDR Readouts For Paltusotine; A Comprehensive Slide Deck
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Resizing for PATHFNDR-2 Bodes Well for Paltusotine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Lines Up Multiple Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Just Bump in the Road for CrineticsÂ’ CRN04777; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
PATHFNDR 1 Finds Its Way to Enrollment Completion
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pipeline Continues to Broaden with CRN04777 Headed for Phase 2, We Expect CRN04894 to Soon Follow; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D